Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338805 · ClinicalTrials.gov registry record · Phase 2
Phase II BGG492 Capsule Extension for Partial Epilepsy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01338805 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT01338805, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
Interventions
- DRUG BGG492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338805
The ClinicalTrials.gov registry entry for NCT01338805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGG492 is the first listed.
NCT01338805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338805 about?
NCT01338805 is a clinical study titled "Phase II BGG492 Capsule Extension for Partial Epilepsy". This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
What is the current status of trial NCT01338805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2011-06. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01338805?
The interventions under investigation include: BGG492 (DRUG).
Who is sponsoring clinical trial NCT01338805?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.